BCL2 and acute myeloid leukemia: In this report, we evaluated the anti-tumor effect of ASP1235 in combination with venetoclax or venetoclax plus azacitidine for THP-1 cells, which are AML-derived cells expressing both FLT3 and Bcl-2.